研究者詳細

顔写真

オノデラ　コウ
小野寺　浩
Ko Onodera
所属
大学院医学系研究科　地域総合診療医育成寄附講座
職名
准教授
学位

  • 医学博士 （東北大学）

経歴 2

  • 2017年10月 ～
    東北大学大学院医学系研究科　地域総合診療医育成寄附講座　准教授

  • 2009年4月 ～
    東北大学　病院（医科診療部門） 移植・再建・内視鏡外科　講師

学歴 2

  • 東北大学　医学系研究科　外科学専攻

    ～ 1997年3月

  • 東北大学　医学部　医学科

    ～ 1989年3月

研究キーワード 7

  • covid-19

  • GATA1

  • small maf

  • nrf2

  • 食道癌

  • 放射線感受性

  • 化学療法感受性

研究分野 2

  • ライフサイエンス / 消化器外科学 /

  • ライフサイエンス / 分子生物学 /

論文 61

  1. Establishment of a Collaborative System for Long COVID Brain Fog Using a Questionnaire and Scoring

    Rie Ono, Shin Takayama, Taizen Nakase, Akiko Kikuchi, Ryutaro Arita, Michiaki Abe, Takeshi Kannno, Ko Onodera, Minoru Osawa, Kota Ishizawa, Natsumi Saito, Tadashi Ishii

    An Official Journal of the Japan Primary Care Association　47　(3)　120-123　2024年9月20日

    出版者・発行元： The Japan Primary Care Association

    DOI： 10.14442/generalist.47.120 　

    ISSN：2185-2928

    eISSN：2187-2791

  2. 東北大学病院総合診療科で経験した視神経脊髄炎スペクトラム障害(NMOSD)の3例

    阿部 倫明, 齊藤 奈津美, 有田 龍太郎, 菅原 章人, 上條 広光, 石沢 興太, 大澤 稔, 高山 真, 小野寺 浩, 石井 正

    日本病院総合診療医学会雑誌　20　(臨増2)　275-275　2024年9月

    出版者・発行元： (一社)日本病院総合診療医学会

    ISSN：2185-8136

    eISSN：2758-7878

  3. Sequential Sampling of the Gastrointestinal Tract to Characterize the Entire Digestive Microbiome in Japanese Subjects

    Kota Ishizawa, Toru Tamahara, Suguo Suzuki, Yutaka Hatayama, Bin Li, Michiaki Abe, Yuichi Aoki, Ryutaro Arita, Natsumi Saito, Minoru Ohsawa, Soichiro Kaneko, Rie Ono, Shin Takayama, Muneaki Shimada, Kazuki Kumada, Tomoyuki Koike, Atsushi Masamune, Ko Onodera, Tadashi Ishii, Ritsuko Shimizu, Takeshi Kanno

    Microorganisms　12　(7)　1324-1324　2024年6月28日

    出版者・発行元： MDPI AG

    DOI： 10.3390/microorganisms12071324 　

    eISSN：2076-2607

    詳細を見る 詳細を閉じる

    The gastrointestinal (GI) tract harbors trillions of microorganisms known to influence human health and disease, and next-generation sequencing (NGS) now enables the in-depth analysis of their diversity and functions. Although a significant amount of research has been conducted on the GI microbiome, comprehensive metagenomic datasets covering the entire tract are scarce due to cost and technical challenges. Despite the widespread use of fecal samples, integrated datasets encompassing the entire digestive process, beginning at the mouth and ending with feces, are lacking. With this study, we aimed to fill this gap by analyzing the complete metagenome of the GI tract, providing insights into the dynamics of the microbiota and potential therapeutic avenues. In this study, we delved into the complex world of the GI microbiota, which we examined in five healthy Japanese subjects. While samples from the whole GI flora and fecal samples provided sufficient bacteria, samples obtained from the stomach and duodenum posed a challenge. Using a principal coordinate analysis (PCoA), clear clustering patterns were identified; these revealed significant diversity in the duodenum. Although this study was limited by its small sample size, the flora in the overall GI tract showed unwavering consistency, while the duodenum exhibited unprecedented phylogenetic diversity. A visual heat map illustrates the discrepancy in abundance, with Fusobacteria and Bacilli dominating the upper GI tract and Clostridia and Bacteroidia dominating the fecal samples. Negativicutes and Actinobacteria were found throughout the digestive tract. This study demonstrates that it is possible to continuously collect microbiome samples throughout the human digestive tract. These findings not only shed light on the complexity of GI microbiota but also provide a basis for future research.

  4. A Case Series of Post-COVID Conditions with Fatigability Treated with Saikokeishito

    Rie Ono, Shin Takayama, Natsumi Saito, Ryutaro Arita, Akiko Kikuchi, Kota Ishizawa, Takeshi Kanno, Akito Sugawara, Minoru Ohsawa, Michiaki Abe, Ko Onodera, Tetsuya Akaishi, Tadashi Ishii

    An Official Journal of the Japan Primary Care Association　47　(2)　49-55　2024年6月20日

    出版者・発行元： The Japan Primary Care Association

    DOI： 10.14442/generalist.47.49 　

    ISSN：2185-2928

    eISSN：2187-2791

  5. COVID-19軽症者等療養施設におけるモルヌピラビルの効果と安全性

    有田 龍太郎, 高山 真, 阿部 倫明, 菊地 章子, 大澤 稔, 小野寺 浩, 菅野 武, 齊藤 奈津美, 赤石 哲也, 小野 理恵, 只野 恭教, 鈴木 聡子, 菅原 章人, 石井 正

    日本プライマリ・ケア連合学会学術大会　14回　219-219　2023年5月

    出版者・発行元： (一社)日本プライマリ・ケア連合学会

  6. COVID-19軽症者等療養施設におけるモルヌピラビルの効果と安全性

    有田 龍太郎, 高山 真, 阿部 倫明, 菊地 章子, 大澤 稔, 小野寺 浩, 菅野 武, 齊藤 奈津美, 赤石 哲也, 小野 理恵, 只野 恭教, 鈴木 聡子, 菅原 章人, 石井 正

    日本プライマリ・ケア連合学会学術大会　14回　219-219　2023年5月

    出版者・発行元： (一社)日本プライマリ・ケア連合学会

  7. Predictors for the Development of Hypoxia or Prolonged Acute Symptoms Among Non-Hospitalized Mild-To-Moderate Patients with Coronavirus Disease 2019

    Yasunori Tadano, Tetsuya Akaishi, Satoko Suzuki, Rie Ono, Natsumi Saito, Ryutaro Arita, Takeshi Kanno, Junichi Tanaka, Akiko Kikuchi, Minoru Ohsawa, Shin Takayama, Michiaki Abe, Ko Onodera, Tadashi Ishii

    The Tohoku Journal of Experimental Medicine　260　(3)　231-244　2023年

    出版者・発行元： Tohoku University Medical Press

    DOI： 10.1620/tjem.2023.j038 　

    ISSN：0040-8727

    eISSN：1349-3329

  8. COVID-19-Related Symptoms during the SARS-CoV-2 Omicron (B.1.1.529) Variant Surge in Japan.

    Tetsuya Akaishi, Shigeki Kushimoto, Yukio Katori, Noriko Sugawara, Hiroshi Egusa, Kaoru Igarashi, Motoo Fujita, Shigeo Kure, Shin Takayama, Michiaki Abe, Akiko Kikuchi, Minoru Ohsawa, Kota Ishizawa, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tadashi Ishii

    The Tohoku journal of experimental medicine　258　(2)　103-110　2022年8月25日

    DOI： 10.1620/tjem.2022.J067 　

    詳細を見る 詳細を閉じる

    The exact profiles of the clinical symptoms related to the SARS-CoV-2 Omicron variant (B.1.1.529) remain largely uncertain. Therefore, this study aimed to clarify the clinical manifestations of infection with this variant. We enrolled individuals who were tested by quantitative nasopharyngeal swab reverse transcription-polymerase chain reaction (RT-PCR) test at a large screening center in a city of Japan during the B.1.1.529 Omicron variant wave between January and May 2022, after contact with COVID-19 patients. Swab tests were planned to be performed approximately 4-5 days after contact. The presence of COVID-19-related symptoms was assessed at the swab test site. Among the 2,507 enrolled individuals, 943 (37.6%) were RT-PCR test-positive and 1,564 (62.4%) were test-negative. Among the 943 PCR test-positive participants, the prevalence of the symptoms was as follows: 47.3% with cough, 32.9% with sore throat, 18.4% with fatigability, 12.7% with fever of ≥ 37.5℃, 9.9% with dyspnea, 2.1% with dysosmia, and 1.4% with dysgeusia. The prevalence of cough, sore throat, dyspnea, and fatigability was higher among adults aged ≥ 18 years than among children and adolescents. The prevalence of dysosmia and dysgeusia remarkably decreased during the Omicron wave (1-3%) compared to during the pre-Omicron variant waves (15-25%). In summary, common COVID-19-related symptoms during the Omicron variant wave included cough and sore throat, followed by fatigability, fever, and dyspnea. The prevalence of most of these symptoms was higher in adults than in non-adults. The prevalence of dysosmia and dysgeusia remarkably decreased with the Omicron variant than with pre-Omicron variants.

  9. Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan 国際誌

    Tetsuya Akaishi, Shigeki Kushimoto, Yukio Katori, Noriko Sugawara, Hiroshi Egusa, Kaoru Igarashi, Motoo Fujita, Shigeo Kure, Shin Takayama, Michiaki Abe, Akiko Kikuchi, Minoru Ohsawa, Kota Ishizawa, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tadashi Ishii

    Scientific Reports　12　(1)　13589-13589　2022年8月10日

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1038/s41598-022-17990-7 　

    eISSN：2045-2322

    詳細を見る 詳細を閉じる

    Abstract The administration of a third booster dose of messenger ribonucleic acid (mRNA) vaccines against coronavirus disease 2019 (COVID-19) has progressed worldwide. Since January 2022, Japan has faced a nationwide outbreak caused by the Omicron variant, which occurred simultaneously with the progression of mass vaccination with the third booster dose. Therefore, this study evaluated the effectiveness of the third dose of vaccine by reverse transcription-polymerase chain reaction (RT-PCR) test using nasopharyngeal swab samples from adults aged ≥ 18 years tested after having close contact with COVID-19 cases between January and May 2022. Participants who completed only one dose were excluded from the study. Among the 928 enrolled participants, 139 had never been vaccinated, 609 had completed two doses, 180 had completed three doses before the swab test, and the overall RT-PCR test positivity rate in each group was 48.9%, 46.0%, and 32.2%, respectively. The vaccine effectiveness of the third dose to prevent infection after close contact was approximately 40% (95% confidence interval: 20–60%), which was the highest at 10–70 days after receiving the third dose. In conclusion, the effectiveness of the three-dose mRNA COVID-19 vaccine after close contact during the Omicron outbreak is approximately 40%.

  10. Response to Glucocorticoid Therapy in Patients with Mild to Moderate Coronavirus Disease 2019 at a Japanese Care Facility.

    Akiko Kikuchi, Ryutaro Arita, Rie Ono, Yasunori Tadano, Natsumi Saito, Tetsuya Akaishi, Takeshi Kanno, Minoru Osawa, Shin Takayama, Michiaki Abe, Ko Onodera, Tadashi Ishii

    The Tohoku journal of experimental medicine　257　(2)　97-106　2022年6月4日

    DOI： 10.1620/tjem.2022.J022 　

    詳細を見る 詳細を閉じる

    The fifth wave of the coronavirus disease 2019 (COVID-19) pandemic caused by delta variant infection depleted medical resources, and the Japanese government announced glucocorticoid use for outpatients. An appropriate outpatient-glucocorticoid treatment for COVID-19 has not been established; therefore, we created treatment manuals with indications for glucocorticoid administration in a care facility adequately equipped to manage patients with mild to moderate COVID-19. Thirty-eight patients (24 males, 14 females; mean age 40.5 ± 11.8 years) were treated with glucocorticoids from August 1 to October 1, 2021 [COVID-19 staging, mild (n = 1), moderate I (n = 19), and moderate II (n = 18)]. Patients were treated with 6.6 mg/day d.i.v. or 6 mg/day p.o. dexamethasone, or 20-30 mg/day p.o. prednisolone. The median (25th-75th percentile) number of days from the date of onset to glucocorticoid administration was 8.0 days (7.0-11.25 days). While 24 patients were hospitalized, the condition of 14 improved without hospitalization. The median number of days from glucocorticoid administration to hospitalization was 1.0 day (range, 1.0-1.0 day). In the non-hospitalized patients, the median number of days of glucocorticoid administration was 5.0 days (5.0-5.25 days). The mean number of days from glucocorticoid administration to discharge from the care facility for non-hospitalized patients was 8.4 ± 3.3 days. The adverse reactions among non-hospitalized patients included insomnia (n = 1) and mild liver dysfunction (n = 3). The present method of glucocorticoid administration can be safely used for patients with COVID-19 in care facilities.

  11. Refractory Chest Pain in Mild to Moderate Coronavirus Disease 2019 Successfully Treated with Saikanto, a Japanese Traditional Medicine.

    Ryutaro Arita, Rie Ono, Natsumi Saito, Satoko Suzuki, Akiko Kikuchi, Minoru Ohsawa, Yasunori Tadano, Tetsuya Akaishi, Takeshi Kanno, Michiaki Abe, Ko Onodera, Shin Takayama, Tadashi Ishii

    The Tohoku journal of experimental medicine　257　(3)　241-249　2022年5月20日

    DOI： 10.1620/tjem.2022.J040 　

    詳細を見る 詳細を閉じる

    Coronavirus disease 2019 (COVID-19) causes a variety of pain symptoms in the acute phase. Severe chest pain suddenly occurs even without abnormalities on examination and is sometimes refractory to analgesics. Such pain is a clinical concern in care facilities with limited resources, and this is the first report on the use of saikanto for its treatment. In Miyagi Prefecture, Japan, COVID-19 patients with mild symptoms were admitted to a hotel that operated as an isolation facility, and their symptoms were observed. In this article, we report four cases in which chest pain comorbid with mild to moderate COVID-19 was successfully treated with saikanto, a traditional Japanese (Kampo) medicine. The patients presented with chest pain and underwent medical examination at the facility. Two patients had severe chest pain refractory to acetaminophen. Critical cardiopulmonary diseases were ruled out in all the patients, and three patients had features of pneumonia on chest radiograph. Medications, including saikanto, were administered to the patients. The patients' chest pain and other symptoms improved 1-4 days after the administration of saikanto, and they left the care facility without hospitalization. The cause of the chest pain experienced by these patients is unclear, but we speculate that it could be minimal pleural inflammation or neuropathy. Previous pharmacological studies have suggested anti-inflammatory and analgesic properties of the crude drugs that constitute saikanto. This case report suggests that saikanto could be a treatment option for chest pain refractory to analgesics in patients with mild to moderate COVID-19.

  12. Effectiveness of mRNA COVID-19 Vaccines in Japan during the Nationwide Pandemic of the Delta Variant.

    Tetsuya Akaishi, Shigeki Kushimoto, Yukio Katori, Noriko Sugawara, Kaoru Igarashi, Motoo Fujita, Shigeo Kure, Shin Takayama, Michiaki Abe, Akiko Kikuchi, Kota Ishizawa, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tadashi Ishii

    The Tohoku journal of experimental medicine　257　(1)　1-6　2022年5月13日

    DOI： 10.1620/tjem.2022.J012 　

    詳細を見る 詳細を閉じる

    The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remained a major global health concern in 2021. To suppress the spread of infection, mass vaccinations have been performed across countries worldwide. In Japan, vaccinations of the first and second doses for most of the nation were performed during the nationwide outbreak of the B.1.617.2 (Delta) variant with the L452R spike protein mutation, and the effectiveness of the vaccinations to suppress the spread of COVID-19 among the people in Japan remains uncertain. In this study, adults aged ≥18 years, who were in contact with patients with COVID-19 and underwent nasopharyngeal swab reverse transcription-polymerase chain reaction (RT-PCR) tests during August and September 2021 at a mass screening test center in Japan, were enrolled. In this period, more than 95% of the COVID-19 infections were reportedly caused by the Delta variant. As a result, a total of 784 adults with recent contact history, including 231 (29.5%) RT-PCR test-positive cases, were enrolled. The test positivity rate was lower in individuals who had been vaccinated twice than in unvaccinated individuals (12.5% vs. 39.0%, p < 0.0001), with the risk ratio of 0.32 (95% confidence interval 0.23-0.46). The vaccine effectiveness was the highest between 7-90 days after the second vaccine dose. In conclusion, two doses of mRNA COVID-19 vaccines effectively suppressed transmission in Japan during the nationwide pandemic of the Delta variant, estimated to have prevented 50-80% of the infection.

  13. COVID-19宿泊療養施設におけるステロイド剤使用経験の報告

    菊地 章子, 小野 理恵, 有田 龍太郎, 只野 恭教, 齊藤 奈津美, 大澤 稔, 阿部 倫明, 高山 真, 小野寺 浩, 石井 正

    日本内科学会雑誌　111　(Suppl.)　214-214　2022年2月

    出版者・発行元： (一社)日本内科学会

    ISSN：0021-5384

    eISSN：1883-2083

  14. COVID-19宿泊療養施設におけるステロイド剤使用経験の報告

    菊地 章子, 小野 理恵, 有田 龍太郎, 只野 恭教, 齊藤 奈津美, 大澤 稔, 阿部 倫明, 高山 真, 小野寺 浩, 石井 正

    日本内科学会雑誌　111　(Suppl.)　214-214　2022年2月

    出版者・発行元： (一社)日本内科学会

    ISSN：0021-5384

    eISSN：1883-2083

  15. COVID-19 Transmission at Schools in Japan.

    Tetsuya Akaishi, Shigeki Kushimoto, Yukio Katori, Noriko Sugawara, Kaoru Igarashi, Motoo Fujita, Shigeo Kure, Shin Takayama, Michiaki Abe, Junichi Tanaka, Akiko Kikuchi, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tadashi Ishii

    The Tohoku journal of experimental medicine　255　(3)　239-246　2021年11月

    DOI： 10.1620/tjem.255.239 　

    詳細を見る 詳細を閉じる

    The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global public health concern in 2021. However, the risk of attending schools during the pandemic remains unevaluated. This study estimated the secondary transmission rate at schools using the results of a real-time reverse transcription-polymerase chain reaction (RT-PCR) screening test performed between July 2020 and April 2021, before starting the nationwide mass vaccination. A total of 1,924 students (20 RT-PCR-positive; 1.0%) from 52 schools or preschools were evaluated, together with 1,379 non-adults (95 RT-PCR-positive; 6.9%) exposed to SARS-CoV-2 in non-school environments. Assuming that the infectious index cases were asymptomatic and the transmission at schools followed a Bernoulli process, we estimated the probability of transmission after each contact at school as approximately 0.005 (0.5% per contact) with the current infection prevention measures at schools in Japan (i.e., hand hygiene, physical distancing, wearing masks, and effective ventilation). Furthermore, assuming that all children are capable of carrying the infection, then contact between an index case and 20-30 students per day at schools would yield the expected value for secondary cases of ≥ 1.0, during the 10 days of the infectious period. In conclusion, with the current infection prevention measures at schools in Japan, secondary transmission at schools would occur in approximately every 200 contacts. When considering this rate, compliance with the current infection prevention measures at schools and early detection and quarantine of the index cases would be effective in preventing the spread of COVID-19 at schools.

  16. Discriminatory Value of Self-reported Olfactory Dysfunction in the Prediction of Coronavirus Disease 2019.

    Tetsuya Akaishi, Shigeki Kushimoto, Yukio Katori, Shigeo Kure, Kaoru Igarashi, Motoo Fujita, Shin Takayama, Michiaki Abe, Akiko Kikuchi, Junichi Tanaka, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tadashi Ishii

    Internal medicine (Tokyo, Japan)　60　(18)　2905-2910　2021年9月15日

    DOI： 10.2169/internalmedicine.7238-21 　

    詳細を見る 詳細を閉じる

    Objective Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), remains the world's largest public health concern in 2021. A history of close contact with infectious patients is a factor that predicts a positive SARS-CoV-2 test result. Meanwhile, the precise predictive value of symptoms suggestive of COVID-19 has not been fully elucidated. This study aimed to clarify the predictive and discriminatory value of each clinical symptom suggestive of COVID-19. Methods This study enrolled participants who were tested for SARS-CoV-2 by reverse transcription polymerase chain reaction using a nasopharyngeal swab between November 2020 and January 2021. All enrolled patients were evaluated for data regarding the presence and closeness of contact with infectious patients and comprehensive clinical features (i.e., fever, cough, dyspnea, fatigue, dysosmia, and dysgeusia). Results Among the 1,744 tested participants, 144 tested positive for SARS-CoV-2. In the test-positive group, self-reported cough, fatigue, dysosmia, and dysgeusia were significant predictors of COVID-19, independent from a history of close contact. In particular, the presence of dysosmia was the strongest predictor of COVID-19 in both univariate and multivariate analyses. Among the 42 patients with self-reported dysosmia, 25 (59.5%) were SARS-CoV-2 test-positive. Self-reported dysosmia was reported by 25 (17.4%) of the 144 patients who tested positive for SARS-CoV-2, and 15 (60.0%) of the 25 COVID-19 patients with dysosmia had accompanying dysgeusia. Conclusion The presence of dysosmia was reported by 10-25% of patients with COVID-19, and is a significant predictor of COVID-19 infection, independent from a history of close contact.

  17. COVID-19 transmission in group living environments and households. 国際誌

    Tetsuya Akaishi, Shigeki Kushimoto, Yukio Katori, Shigeo Kure, Kaoru Igarashi, Shin Takayama, Michiaki Abe, Junichi Tanaka, Akiko Kikuchi, Ko Onodera, Tadashi Ishii

    Scientific reports　11　(1)　11616-11616　2021年6月2日

    DOI： 10.1038/s41598-021-91220-4 　

    詳細を見る 詳細を閉じる

    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the world's largest public health concern. This study evaluated COVID-19 transmission risks in people in group living environments. A total of 4550 individuals with a history of recent contact with patients at different places (dormitory/home/outside the residences) and levels (close/lower-risk) were tested for SARS-CoV-2 viral RNA using a nasopharyngeal swab test between July 2020 and May 2021. The test-positive rate was highest in individuals who had contact in dormitories (27.5%), but the rates were largely different between dormitories with different infrastructural or lifestyle features and infection control measures among residents. With appropriate infection control measures, the secondary transmission risk in dormitories was adequately suppressed. The household transmission rate (12.6%) was as high as that of close contact outside the residences (11.3%) and accounted for > 60% of the current rate of COVID-19 transmission among non-adults. Household transmission rates synchronized to local epidemics with changed local capacity of quarantining infectious patients. In conclusion, a group living environment is a significant risk factor of secondary transmission. Appropriate infection control measures and quarantine of infectious residents will decrease the risk of secondary transmission in group living environments.

  18. Treatment of COVID-19-Related Olfactory Disorder Promoted by Kakkontokasenkyushin'i: A Case Series.

    Shin Takayama, Ryutaro Arita, Rie Ono, Natsumi Saito, Satoko Suzuki, Akiko Kikuchi, Minoru Ohsawa, Yasunori Tadano, Tetsuya Akaishi, Junichi Tanaka, Takeshi Kanno, Michiaki Abe, Ko Onodera, Tadashi Ishii

    The Tohoku journal of experimental medicine　254　(2)　71-80　2021年6月

    DOI： 10.1620/tjem.254.71 　

    詳細を見る 詳細を閉じる

    Olfactory disorders are one of the characteristic symptoms of the coronavirus disease of 2019 (COVID-19), which causes infection and inflammation of the upper and lower respiratory tract. To our knowledge, there are no treatments for COVID-19-related olfactory disorder. Here, we report five olfactory disorder cases in COVID-19, treated using the Japanese traditional (Kampo) medicine, kakkontokasenkyushin'i. We treated five patients with mild COVID-19 at an isolation facility using Kampo medicine, depending on their symptoms. Patients with the olfactory disorder presented with a blocked nose, nasal discharge or taste impairment. Physical examination using Kampo medicine showed similar findings, such as a red tongue with red spots and sublingual vein congestion, which presented as blood stasis and inflammation; thus, we prescribed the Kampo medicine, kakkontokasenkyushin'i. After administration, the numeric rating scale scores of the smell impairment improved within 3 days from 9 to 3 in case 1, from 10 to 0 in case 2, from 9 to 0 in case 3, from 5 to 0 in case 4, and from 9 to 0 within 5 days in case 5. Following the treatment, other common cold symptoms were also alleviated. Kakkontokasenkyushin'i can be used for treating nasal congestion, rhinitis, and inflammation in the nasal mucosa. The olfactory disorder in COVID-19 has been reportedly associated with inflammation and congestion, especially in the olfactory bulb and olfactory cleft. Kakkontokasenkyushin'i may be one of the treatment alternatives for the olfactory disorder with rhinitis in patients with COVID-19.

  19. Impacts of Natural Environmental Factors and Prevalence of Airway Symptoms on the Local Spread of COVID-19: A Time-Series Analysis in Regional COVID-19 Epidemics.

    Tadashi Ishii, Shigeki Kushimoto, Yukio Katori, Shigeo Kure, Kaoru Igarashi, Motoo Fujita, Noriko Sugawara, Shin Takayama, Michiaki Abe, Junichi Tanaka, Akiko Kikuchi, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tetsuya Akaishi

    The Tohoku journal of experimental medicine　254　(2)　89-100　2021年6月

    DOI： 10.1620/tjem.254.89 　

    詳細を見る 詳細を閉じる

    Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the world's largest public health concern in 2021. This study evaluated the associations of the prevalence of airway symptoms among the tested individuals and data regarding the natural environmental factors with the weekly number of newly diagnosed COVID-19 patients in Sendai City (Nt). For the derivatives of the screening test results, data from individuals with a contact history who underwent nasopharyngeal swab reverse transcription-polymerase chain reaction (RT-PCR) testing between July 2020 and April 2021 (6,156 participants, including 550 test-positive patients) were used. The value of Nt correlated with the weekly RT-PCR test-positive rate after close contact, prevalence of cough symptoms in test-positive individuals or in test-negative individuals, lower air temperature, lower air humidity, and higher wind speed. The weekly test-positive rate correlated with lower air humidity and higher wind speed. In cross-correlation analyses, natural environmental factors correlated with the regional epidemic status on a scale of months, whereas the airway symptoms among non-COVID-19 population affected on a scale of weeks. When applying an autoregression model to the serial data of Nt, large-scale movements of people were suggested to be another factor to influence the local epidemics on a scale of days. In conclusion, the prevalence of cough symptoms in the local population, lower air humidity or higher wind speed, and large-scale movements of people in the locality would jointly influence the local epidemic status of COVID-19.

  20. Predictors of SARS-CoV-2 Positivity Based on RT-PCR Swab Tests at a Drive-Through Outpatient Clinic for COVID-19 Screening in Japan.

    Tadashi Ishii, Shigeki Kushimoto, Yukio Katori, Shigeo Kure, Kaoru Igarashi, Motoo Fujita, Shin Takayama, Michiaki Abe, Junichi Tanaka, Akiko Kikuchi, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tetsuya Akaishi

    The Tohoku journal of experimental medicine　253　(2)　101-108　2021年2月

    DOI： 10.1620/tjem.253.101 　

    詳細を見る 詳細を閉じる

    In response to the COVID-19 pandemic caused by SARS-CoV-2 in 2020, we conducted drive-through nasopharyngeal swab testing for COVID-19 in Sendai city, Japan, since April 2020. All tested individuals were judged in advance by public health centers for the necessity of undergoing the test with possible contact history and/or symptoms suggestive of COVID-19. In this study, to identify the predictors of SARS-CoV-2 test positivity for more efficient and evidenced selection of suspected individuals, we enrolled 3,540 consecutive individuals, tested in the first 7 months of the testing program, with data regarding to the history of close contact with COVID-19 patients, including those involved in cluster outbreaks. This cohort included 284 foreign students (257 males and 27 females) from a vocational school involved in the largest cluster outbreak in the area. Close contact history was present in 952 (26.9%) of the participants. The reverse transcription-polymerase chain reaction (RT-PCR) test results showed that 164 participants (4.6%) were positive and 3,376 participants (95.4%) were negative for the SARS-CoV-2 nucleocapsid gene (N2). In the univariate and multivariate analyses, history of close contact with COVID-19 patients, higher age, cough symptoms, and non-native ethnicity were predictors for SARS-CoV-2 test positivity. However, the significance of age and foreign nationality disappeared or declined upon excluding the foreign students from the aforementioned largest cluster outbreak. In conclusion, a history of close contact with COVID-19 patients and the presence of cough symptoms are significant predictors of SARS-CoV-2 test positivity.

  21. Somatic symptoms with psychogenic or psychiatric background: Characteristics and pitfalls

    Tetsuya Akaishi, Michiaki Abe, Atsuko Masaura, Junichi Tanaka, Shin Takayama, Ko Onodera, Takehiro Numata, Kota Ishizawa, Satoko Suzuki, Minoru Ohsawa, Takeshi Kanno, Tadashi Ishii

    Journal of Family Medicine and Primary Care　10　(2)　1021-1021　2021年

    出版者・発行元： Medknow

    DOI： 10.4103/jfmpc.jfmpc_1100_20 　

    ISSN：2249-4863

  22. Predictors of SARS-CoV-2 Positivity Based on RT-PCR Swab Tests at a Drive-Through Outpatient Clinic for COVID-19 Screening in Japan

    Tadashi Ishii, Shigeki Kushimoto, Yukio Katori, Shigeo Kure, Kaoru Igarashi, Motoo Fujita, Shin Takayama, Michiaki Abe, Junichi Tanaka, Akiko Kikuchi, Yoshiko Abe, Hiroyuki Imai, Yohei Inaba, Yoko Iwamatsu-Kobayashi, Takashi Nishioka, Ko Onodera, Tetsuya Akaishi

    The Tohoku Journal of Experimental Medicine　253　(2)　101-108　2021年

    出版者・発行元： Tohoku University Medical Press

    DOI： 10.1620/tjem.253.101 　

    ISSN：0040-8727

    eISSN：1349-3329

  23. 経口アルカリ性化剤治療による早朝尿pHと随時尿pHの変動から腎保護効果をどう考えるか 査読有り

    阿部 倫明, 赤石 哲也, 田中 淳一, 石沢 興太, 高山 真, 小野寺 浩, 石井 正

    日本病院総合診療医学会雑誌　15　(6)　583-583　2019年11月

    出版者・発行元： (一社)日本病院総合診療医学会

    ISSN：2185-8136

  24. 大学病院総合診療科初診患者のうつ状態を評価するためのハミルトンうつ病評価尺度の有用性 査読有り

    阿部 倫明, 野崎 裕之, 中川 高, 八木橋 真央, 石沢 興太, 奥田 拓史, 赤石 哲也, 田中 淳一, 大澤 稔, 沼田 健裕, 菊地 章子, 高山 真, 奈良 正之, 小野寺 浩, 富田 博秋, 石井 正

    日本病院総合診療医学会雑誌　14　(6)　556-563　2018年11月

    出版者・発行元： (一社)日本病院総合診療医学会

    ISSN：2185-8136

  25. 医学生の地域医療に関する意識調査 査読有り

    小野寺 浩, 高山 真, 田中 淳一, 石井 正

    日本病院総合診療医学会雑誌　14　(6)　631-631　2018年11月

    出版者・発行元： (一社)日本病院総合診療医学会

    ISSN：2185-8136

  26. Treatment of spontaneous esophageal rupture (Boerhaave syndrome) using thoracoscopic surgery and sivelestat sodium hydrate. 国際誌

    Hiroshi Okamoto, Ko Onodera, Rikiya Kamba, Yusuke Taniyama, Tadashi Sakurai, Takahiro Heishi, Jin Teshima, Makoto Hikage, Chiaki Sato, Shota Maruyama, Yu Onodera, Hirotaka Ishida, Takashi Kamei

    Journal of thoracic disease　10　(4)　2206-2212　2018年4月

    DOI： 10.21037/jtd.2018.03.136 　

    詳細を見る 詳細を閉じる

    BACKGROUND: The mortality rate of spontaneous esophageal rupture remains 20% to 40% due to severe respiratory failure. We have performed thoracoscopic surgery for esophageal disease at our department since 1994. Sivelestat sodium hydrate reportedly improves the pulmonary outcome in the patients with acute lung injury (ALI). METHODS: We retrospectively evaluated the usefulness of thoracoscopic surgery and perioperative administration of sivelestat sodium hydrate for spontaneous esophageal rupture in 12 patients who underwent thoracoscopy at our department between 2002 and 2014. RESULTS: The patient cohort included 11 males and one female (median age, 61 years). The lower left esophageal wall was perforated in all patients. Surgical procedures consisted of thoracoscopic suture and thoracic drainage in six patients, transhiatal suture and thoracoscopic thoracic drainage in five, and thoracoscopic esophagectomy and thoracic drainage in one. The median time from onset to surgery was 8 hours with a surgical duration of 210 minutes, blood loss 260 mL, postoperative ventilator management 1 day, intensive care unit (ICU) stay 5 days, and interval to restoration of oral ingestion 13 days. Postoperative complications included respiratory failure in four patients, pyothorax in three, and leakage in one. There was no instance of perioperative mortality. Regarding perioperative administration of sivelestat sodium hydrate, the postoperative arterial oxygen partial pressure-to-fractional inspired oxygen ratio (P/F) and C-reactive protein (CRP) levels in the administration group were significantly better than those in the non-administration group on postoperative days 4 (P=0.035) and 5 (P=0.037), respectively. In contrast, there was no significant difference between the groups in median time of ventilator management, ICU stay, oral ingestion following surgery, or hospital stay. CONCLUSIONS: Thoracoscopic surgery obtained acceptable results in all patients, including two with a significant time elapse from onset to treatment. Furthermore, sivelestat sodium hydrate was suggested to help improve postoperative respiration and inflammatory response.

  27. Thoracoscopic primary repair with mediastinal drainage is a viable option for patients with Boerhaave's syndrome. 国際誌

    Toru Nakano, Ko Onodera, Hirofumi Ichikawa, Takashi Kamei, Yusuke Taniyama, Tadashi Sakurai, Go Miyata

    Journal of thoracic disease　10　(2)　784-789　2018年2月

    DOI： 10.21037/jtd.2018.01.50 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Spontaneous esophageal rupture (Boerhaave's syndrome) is an emergency that can cause life-threatening conditions. Various procedures have been used to treat Boerhaave's syndrome. However, a standard surgical procedure has not been established. Herein, we report our experience with primary suture of the ruptured esophagus via a thoracoscopy or laparotomy. METHODS: Between November 2002 and May 2015, 11 patients with Boerhaave's syndrome presented to our department and were managed using one of two surgical procedures based on the surgeon's discretion. Six patients underwent a thoracoscopic primary suture and drainage (group A); 5 patients underwent a primary suture via laparotomy followed by thoracoscopic drainage (group B). Patient medical records were retrospectively reviewed. RESULTS: The mean interval between initial perforation and surgery was 13.7 h (group A) and 17.2 h (group B) (P=0.7307). The mean operative time was 190 min (group A) and 249 min (group B) (P=0.106). Patient baseline characteristics and surgical outcomes were similar for both surgical procedures. One patient in each group experienced postoperative leakage that did not require surgical intervention. CONCLUSIONS: The results suggest that thoracoscopic esophageal repair, as well as suturing via laparotomy, is a good surgical alternative for patients with Boerhaave's syndrome.

  28. Thoracoscopic esophagectomy for esophageal cancer with situs inversus totalis: a case report and literature review.

    Naoto Ujiie, Toru Nakano, Takashi Kamei, Hirofumi Ichikawa, Go Miyata, Ko Onodera, Noriaki Ohuchi

    General thoracic and cardiovascular surgery　64　(6)　359-62　2016年6月

    DOI： 10.1007/s11748-016-0639-y 　

    詳細を見る 詳細を閉じる

    A 63-year-old male visited our hospital, complaining of discomfort when swallowing. Upper gastrointestinal endoscopy revealed a type 2 tumor in the middle thoracic esophagus, which was diagnosed as squamous cell carcinoma by endoscopic biopsy. Computed tomography revealed situs inversus totalis (SIT). We assessed the relationship of the esophagus with neighboring organs using preoperative three-dimensional imaging. We performed thoracoscopic esophagectomy with radical lymph node dissection in the right decubitus position and hand-assisted laparoscopic gastric mobilization in the supine position. The definitive diagnosis was squamous cell carcinoma, pT2N1M0, pStage IIB according to the Union for International Cancer Control. The patient's postoperative course was uneventful, and 5 years post-operation, he is alive without recurrence. In SIT patients, surgical procedures are difficult because of anatomic transposition. Three-dimensional imaging effectively assesses the anatomical structure and contributes to safer thoracoscopic esophagectomy for esophageal cancer patients with SIT. Relevant literature is also discussed and reviewed.

  29. 特発性食道破裂手術における胸腔鏡およびシベレスタットナトリウムの有用性の検討 査読有り

    岡本 宏史, 小野寺 浩, 菊地 寛, 神波 力也, 中野 徹, 谷山 裕亮, 櫻井 直, 佐藤 千晃, 神谷 蔵人, 小澤 洋平, 亀井 尚

    日本外科学会定期学術集会抄録集　116回　PS-4　2016年4月

    出版者・発行元： (一社)日本外科学会

  30. 献腎移植後に発症した食道憩室穿孔に対し胸腔鏡下食道切除を施行した1例 査読有り

    福富 俊明, 亀井 尚, 中野 徹, 谷山 裕亮, 櫻井 直, 日景 允, 手島 仁, 佐藤 千晃, 伊藤 想一, 岡本 宏史, 新妻 展近, 神谷 蔵人, 小澤 洋平, 小野寺 浩, 大内 憲明

    日本内視鏡外科学会雑誌　20　(7)　OS210-5　2015年12月

    出版者・発行元： (一社)日本内視鏡外科学会

    ISSN：1344-6703

    eISSN：2186-6643

  31. Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients 査読有り

    K. Jingu, H. Matsushita, K. Takeda, K. Narazaki, H. Ariga, R. Umezawa, T. Sugawara, G. Miyata, K. Onodera, K. Nemoto, S. Yamada

    DISEASES OF THE ESOPHAGUS　26　(5)　522-527　2013年7月

    DOI： 10.1111/j.1442-2050.2012.01396.x 　

    ISSN：1120-8694

    eISSN：1442-2050

  32. Esophagectomy using a thoracoscopic approach with an open laparotomic or hand-assisted laparoscopic abdominal stage for esophageal cancer: analysis of survival and prognostic factors in 315 patients. 国際誌

    Hirofumi Ichikawa, Go Miyata, Shukichi Miyazaki, Ko Onodera, Takashi Kamei, Tohru Hoshida, Hiroshi Kikuchi, Rikiya Kanba, Toru Nakano, Takashi Akaishi, Susumu Satomi

    Annals of surgery　257　(5)　873-85　2013年5月

    DOI： 10.1097/SLA.0b013e31826c87cd 　

    詳細を見る 詳細を閉じる

    UNLABELLED: Survival and prognostic factors were analyzed in 315 patients with esophageal cancer undergoing thoracoscopic-assisted esophagectomy (TAE). The 5-year survival rate of 57.8% was satisfactory, indicating the oncological feasibility of TAE. Perioperative outcomes affected overall survival in the whole cohort but not in the subgroup treated with 2 endoscopic stages. OBJECTIVE: To estimate the oncological feasibility of thoracoscopic-assisted esophagectomy (TAE) for esophageal cancer and to clarify the prognostic impact of perioperative factors after TAE. BACKGROUND: Favorable perioperative outcomes of TAE versus open surgery have been demonstrated. However, survival data after TAE in a large cohort are limited, and no information on the prognostic influence of perioperative factors after TAE is available. METHODS: Prospectively collected data for 315 patients undergoing TAE for esophageal cancer were analyzed. Survival was compared with the Kaplan-Meier analysis and Cox regression analysis between 2 surgical approaches: thoracoscopic and hand-assisted laparoscopic esophagectomy (THLE) and thoracoscopic and open laparotomic esophagectomy (TOE). Factors affecting overall survival were identified with Cox multivariate regression analysis in the whole cohort and the THLE subgroup. RESULTS: THLE and TOE were performed in 153 and 162 patients, respectively. The overall 5-year survival of the whole cohort was 57.8%, with no difference between the THLE and the TOE group. Multivariate analysis of the 315 patients identified the following prognostic factors: blood loss, blood transfusion, intensive care unit stay, cardiovascular complications, pathological T and N stages, lymphatic invasion, intramural metastasis, and number of metastatic nodes. In the THLE subgroup, cerebral comorbidity, histological subtype, pathological T stage, and number of metastatic nodes were independent prognostic factors. CONCLUSIONS: TAE was oncologically feasible. Perioperative factors affected survival in the whole cohort, but did not in the THLE subgroup. However, the reduced perioperative factor effect in this subgroup would be small because the survival rates of the 2 surgical approaches were equal.

  33. A case of verrucous carcinoma of the esophagus associated with difficult histopathological diagnosis of endoscopic biopsy specimens 査読有り

    Yusuke Taniyama, Fumiyoshi Fujishima, Kaiyo Takubo, Tadashi Sakurai, Hiroshi Okamoto, Toru Nakano, Tadashi Kamei, Hirofumi Ichikawa, Ko Onodera, Go Miyata, Hironobu Sasano, Susumu Satomi

    ESOPHAGUS　9　(4)　223-227　2012年12月

    DOI： 10.1007/s10388-012-0320-1 　

    ISSN：1612-9059

  34. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. 査読有り

    Takaya Kai, Suzuki Takafumi, Motohashi Hozumi, Onodera Ko, Satomi Susumu, Kensler Thomas W, Yamamoto Masayuki

    Free Radic Biol Med　53　(4)　817-827　2012年8月15日

    DOI： 10.1016/j.freeradbiomed.2012.06.023 　

  35. Long-Term Results of Radiochemotherapy for Solitary Lymph Node Metastasis After Curative Resection of Esophageal Cancer 査読有り

    Keiichi Jingu, Hisanori Ariga, Kenji Nemoto, Kakutaro Narazaki, Rei Umezawa, Ken Takeda, Masashi Koto, Toshiyuki Sugawara, Masaki Kubozono, Go Miyata, Ko Onodera, Shogo Yamada

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　83　(1)　172-177　2012年5月

    DOI： 10.1016/j.ijrobp.2011.06.1978 　

    ISSN：0360-3016

  36. Early-stage primary malignant melanoma of the esophagus detected simultaneously with esophageal squamous cell carcinoma 査読有り

    Makoto Hikage, Takashi Kamei, Fumiyoshi Fujishima, Go Miyata, Ko Onodera, Hirofumi Ichikawa, Toru Hoshida, Hiroshi Kikuchi, Toru Nakano, Jin Teshima, Motoo Fujita, Hironobu Sasano, Susumu Satomi

    ESOPHAGUS　9　(1)　33-38　2012年3月

    DOI： 10.1007/s10388-011-0300-x 　

    ISSN：1612-9059

  37. 多彩な組織像を呈したalpha-fetoprotein産生Barrett食道癌の1例 査読有り

    武山 大輔, 宮田, 剛, 小野寺, 浩, 市川, 宏文, 亀井, 尚, 星田, 徹, 菊池, 寛, 中野, 徹, 藤島, 史喜, 里見 進

    日本消化器外科学会雑誌　45　(8)　834-841　2012年

    DOI： 10.5833/jjgs.45.834 　

    ISSN：0386-9768 1348-9372

  38. AFP産生食道腺癌の3例

    武山大輔, 宮田剛, 小野寺浩, 市川宏文, 亀井尚, 星田徹, 菊池寛, 中野徹, 藤島史喜, 里見進

    日本食道学会学術集会プログラム・抄録集　65回　349-349　2011年9月

  39. 根治的CRT後サルベージ手術標本における病理学的因子からみた遺残例・再発例の比較

    岡本宏史, 藤島史喜, 宮田剛, 小野寺浩, 市川宏文, 亀井尚, 星田徹, 菊池寛, 中野徹, 里見進

    日本食道学会学術集会プログラム・抄録集　65回　348-348　2011年9月

  40. ステージI食道癌の治療戦略 手術可能と不可stage I食道癌に対する放射線化学療法 2つの前向き試験長期成績比較

    神宮啓一, 有賀久哲, 奈良崎覚太朗, 武田 賢, 梅澤玲, 菅原俊幸, 山田章吾, 宮田剛, 小野寺浩, 根本建二

    日本食道学会学術集会プログラム・抄録集 65回　97-97　2011年9月

  41. 切除可能食道癌に対する治療戦略 salvage治療を付加した化学放射線療法と根治手術の成績 招待有り 査読有り

    亀井尚, 宮田剛, 小野寺浩, 市川宏文, 菊池寛, 中野徹, 里見進

    臨床消化器内科　26　(10)　1381-1387　2011年8月

    出版者・発行元： (株)日本メディカルセンター

    ISSN：0911-601X

    eISSN：2433-2488

  42. 頸部食道癌の治療 手術と化学放射線療法の接点 放射線による頸部食道癌治療

    有賀久哲, 小川芳弘, 武田 賢, 小藤昌志, 菅原俊幸, 清水栄二, 宮田剛, 小野寺浩, 山田章吾

    日本食道学会学術集会プログラム・抄録集　117-117　2010年8月

  43. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. 国際誌

    Hisanori Ariga, Kenji Nemoto, Shukichi Miyazaki, Takashi Yoshioka, Yohishiro Ogawa, Toru Sakayauchi, Keiichi Jingu, Go Miyata, Ko Onodera, Hirofumi Ichikawa, Takashi Kamei, Shunsuke Kato, Chikashi Ishioka, Susumu Satomi, Shogo Yamada

    International journal of radiation oncology, biology, physics　75　(2)　348-56　2009年10月1日

    DOI： 10.1016/j.ijrobp.2009.02.086 　

    詳細を見る 詳細を閉じる

    PURPOSE: Esophagectomy remains the mainstay treatment for esophageal cancer, although retrospective studies have suggested that chemoradiotherapy (CRT) is as effective as surgery. To determine whether CRT can substitute for surgery as the primary treatment modality, we performed a prospective direct comparison of outcomes after treatment in patients with resectable esophageal cancer who had received CRT and those who had undergone surgery. METHODS AND MATERIALS: Eligible patients had resectable T1-3N0-1M0 thoracic esophageal cancer. After the surgeon explained the treatments in detail, the patients selected either CRT (CRT group) or surgery (OP group). The CRT course consisted of two cycles of cisplatin and fluorouracil with split-course concurrent radiotherapy of 60Gy in 30 fractions. Patients with progressive disease during CRT and/or with persistent or recurrent disease after CRT underwent salvage resection. RESULTS: Of 99 eligible patients with squamous cell carcinoma registered between January 2001 and December 2005, 51 selected CRT and 48 selected surgery. Of the patients in the CRT group, 13 (25.5%) underwent esophagectomy as salvage therapy. The 3- and 5-year survival rates were 78.3% and 75.7%, respectively, in the CRT group compared with 56.9% and 50.9%, respectively, in the OP group (p = 0.0169). Patients in the OP group had significantly more metastatic recurrence than those in the CRT group. CONCLUSIONS: Treatment outcomes among patients with resectable thoracic esophageal squamous cell carcinoma were comparable or superior after CRT (with salvage therapy if needed) to outcomes after surgery alone.

  44. 食道類基底細胞癌と扁平上皮癌の臨床病理学的比較検討

    武山大輔, 宮崎修吉, 宮田剛, 小野寺浩, 市川宏文, 亀井尚, 星田徹, 藤島史喜, 笹野公伸, 里見進

    日本消化器外科学会雑誌　42　(7)　1125-1125　2009年7月

  45. CRT-saivage治療の成績からみた食道癌初回治療の選択 招待有り 査読有り

    亀井尚, 宮崎修吉, 宮田剛, 小野寺浩, 市川宏文, 星田徹, 菊池寛, 神波力也, 中野徹, 里見進

    癌の臨床　55　(1)　21-29　2009年1月

  46. 食道癌放射線化学療法後のsalvage手術の意義と適応 招待有り

    亀井尚, 宮崎修吉, 宮田剛, 小野寺浩, 市川宏文, 星田徹, 菊池寛, 神波力也, 中野徹, 里見進

    癌の臨床　53　(10)　647-655　2007年10月

  47. Systemic sarcoidosis associated with double cancers of the esophagus and stomach 査読有り

    Osamu Usami, Masayuki Nara, Tsutomu Tamada, Tomomi Kitamuro, Masafumi Tomaki, Yugo Ashino, Ko Onodera, Shukichi Miyazaki, Takuya Moriya, Toshio Hattori

    INTERNAL MEDICINE　46　(24)　2019-2022　2007年

    DOI： 10.2169/internalmedicine.46.0231 　

    ISSN：0918-2918

  48. Esophageal gastrointestinal stromal tumors (GISTs): Report of three cases 査読有り

    Takashi Kamei, Shukichi Miyazaki, Go Miyata, Takahiro Mori, Ko Onodera, Hirofumi Ichikawa, Hiroshi Kikuchi, Rikiya Kanba, Susumu Satomi

    Esophagus　2　(4)　209-216　2005年12月

    DOI： 10.1007/s10388-005-0057-1 　

    ISSN：1612-9059 1612-9067

  49. Preoperative radiation therapy Is an Independent and strong risk factor for late non-cancer death after esophagectomy. 査読有り

    Mori T Miyazaki, S Miyata G Sugawara, K Onodera, K Ichikawa, H, Kamei T, Kikuchi H Kanba, R, Satomi S

    Interdisciplinary Information Science　11　(2)　141-147　2005年10月

    出版者・発行元： 東北大学

    DOI： 10.4036/iis.2005.141 　

    ISSN：1340-9050

    詳細を見る 詳細を閉じる

    Objective: The aim of this study was to reveal the factors that influence the prognosis of esophageal cancer patients, especially from the other causes than esophageal cancer in the follow-up period after esophagectomy.Method: All of 523 patients with esophageal carcinoma who underwent esophagectomy in a single institute between 1986 and 1999 were followed-up until the end of October 2003. Their prognoses were reviewed and compared by the presence of pre/post-operative radiation, pre/post-operative chemotherapy, surgical procedure, and pathological stages of tumors as well as preoperative general conditions by uni- and multivariate analyses. Results: Univariate analysis revealed that sex (male against female) (p=0.005), abnormality on ECG (p=0.012), and the presence of preoperative radiation (p=0.016) significantly increased the incidence of non-esophageal cancer death; on the other hand, thoracoscopic approach decreased the incidence of non-esophageal cancer death. Multivariate analyses revealed that the presence of preoperative radiation significantly increased mortality due to non-esophageal cancer causes to a 3.70 hazard ratio (95% CI [95% Confidence Interval]; 1.33?10.61).Conclusions: This study clearly showed the late effect of preoperative radiation for carcinoma of the esophagus on the postoperative prognosis, especially in terms of later mortality from causes other than esophageal carcinoma.

  50. 食道領域のChemoradiation 切除可能食道癌に対する化学放射線療法 治療成績と問題点 査読有り

    根本建二, 野宮琢磨, 山田章吾, 小野寺浩, 宮崎修吉, 里見進, 吉岡孝志

    日本気管食道科学会会報　56　(2)　185-186　2005年10月

    DOI： 10.2468/jbes.56.185 　

  51. 食道癌に対する化学放射線療法の現状と展望 査読有り

    本建二, 小川芳弘, 高井憲司, 坂谷内徹, 菅原俊幸, 神宮啓一, 小野寺浩, 宮崎修吉, 里見進, 吉岡孝, 高井良尋, 山田章吾

    臨床放射線　50　(8)　947-953　2005年10月

  52. Use of the pinna reflex as a test of hearing in mutant mice 査読有り

    MA Cheatham, M Pearce, CP Richter, K Onodera, JA Shavit

    AUDIOLOGY AND NEURO-OTOLOGY　6　(2)　79-86　2001年3月

    DOI： 10.1159/000046813 　

    ISSN：1420-3030

  53. One enhancer mediates mafK transcriptional activation in both hematopoietic and cardiac muscle cells 査読有り

    F Katsuoka, H Motohashi, K Onodera, N Suwabe, JD Engel, M Yamamoto

    EMBO JOURNAL　19　(12)　2980-2991　2000年6月

    DOI： 10.1093/emboj/19.12.2980 　

    ISSN：0261-4189

    eISSN：1460-2075

  54. Perinatal synthetic lethality and hematopoietic defects in compound mafG : mafK mutant mice 査読有り

    K Onodera, JA Shavit, H Motohashi, M Yamamoto, JD Engel

    EMBO JOURNAL　19　(6)　1335-1345　2000年3月

    DOI： 10.1093/emboj/19.6.1335 　

    ISSN：0261-4189

  55. Characterization of the murine mafF gene 査読有り

    K Onodera, JA Shavit, H Motohashi, F Katsuoka, JE Akasaka, JD Engel, M Yamamoto

    JOURNAL OF BIOLOGICAL CHEMISTRY　274　(30)　21162-21169　1999年7月

    DOI： 10.1074/jbc.274.30.21162 　

    ISSN：0021-9258

  56. Rescue of the embryonic lethal hematopoietic defect reveals a critical role for GATA-2 in urogenital development 査読有り

    YH Zhou, KC Lim, K Onodera, S Takahashi, J Ohta, N Minegishi, FY Tsai, SH Orkin, M Yamamoto, JD Engel

    EMBO JOURNAL　17　(22)　6689-6700　1998年11月

    DOI： 10.1093/emboj/17.22.6689 　

    ISSN：0261-4189

    eISSN：1460-2075

  57. Impaired megakaryopoiesis and behavioral defects in mafG-null mutant mice 査読有り

    JA Shavit, H Motohashi, K Onodera, J Akasaka, M Yamamoto, JD Engel

    GENES & DEVELOPMENT　12　(14)　2164-2174　1998年7月

    ISSN：0890-9369

  58. Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene 査読有り

    S Takahashi, K Onodera, H Motohashi, N Suwabe, N Hayashi, N Yanai, Y Nabesima, M Yamamoto

    JOURNAL OF BIOLOGICAL CHEMISTRY　272　(19)　12611-12615　1997年5月

    DOI： 10.1074/jbc.272.19.12611 　

    ISSN：0021-9258

  59. GATA-1 transcription is controlled by distinct regulatory mechanisms during primitive and definitive erythropoiesis 査読有り

    K Onodera, S Takahashi, S Nishimura, J Ohta, H Motohashi, K Yomogida, N Hayashi, JD Engel, M Yamamoto

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA　94　(9)　4487-4492　1997年4月

    DOI： 10.1073/pnas.94.9.4487 　

    ISSN：0027-8424

  60. Conserved structure, regulatory elements, and transcriptional regulation from the GATA-1 gene testis promoter 査読有り

    K Onodera, K Yomogida, N Suwabe, S Takahashi, Y Muraosa, N Hayashi, E Ito, L Gu, M Rassoulzadegan, JD Engel, M Yamamoto

    JOURNAL OF BIOCHEMISTRY　121　(2)　251-263　1997年2月

    ISSN：0021-924X

    eISSN：1756-2651

  61. Mesodermal- vs neuronal-specific expression of MafK is elicited by different promoters 査読有り

    H Motohashi, K Igarashi, K Onodera, S Takahashi, H Ohtani, M Nakafuku, M Nishizawa, JD Engel, M Yamamoto

    GENES TO CELLS　1　(2)　223-238　1996年2月

    ISSN：1356-9597

︎全件表示 ︎最初の5件までを表示

MISC 30

  1. 脱毛治療でグリチルリチン酸内服後、偽性アルドステロン症から横紋筋融解症をきたした1例

    小野寺 浩, 阿部 倫明, 高山 真, 高橋 雄大, 松本 宏, 石井 正

    日本病院総合診療医学会雑誌　17　(4)　434-436　2021年7月

    出版者・発行元： (一社)日本病院総合診療医学会

    ISSN： 2185-8136

    詳細を見る 詳細を閉じる

    63歳女性。脱毛治療としてグリチルリチン酸配合錠を2ヵ月内服したところ、両側大腿と肩の筋肉痛が出現し、近医より当院へ紹介となった。臨床経過および検査所見から、本症例は低カルシウム血症により横紋筋融解症をきたしてると判断した。原因としてグリチルリチン酸内服による偽性アルドステロン症が考えられたことから、入院後、補液およびアスパラギン酸カリウムの内服に加え、経静脈的にカリウム補給を行った。その結果、入院10日目にはカリウム値とCK値は正常化、症状の改善が得られ、退院となった。

  2. Hyperosmolar hyperglycemic nonketotic coma after chemoradiotherapy for esophageal cancer

    Toni Nakano, Go Miyata, Ko Onodera, Hirofumi Ichikawa, Takashi Kamei, Tohru Hoshida, Hiroshi Kikuchi, Keiichi Jingu, Noriaki Ohuchi

    ESOPHAGUS　11　(4)　273-276　2014年9月

    DOI： 10.1007/s10388-013-0405-5 　

    ISSN： 1612-9059

    eISSN： 1612-9067

  3. 根治的放射線化学療法後に胸腔鏡下リンパ節郭清術を行った食道癌の3例

    小野寺 浩, 宮田 剛, 市川 宏文, 亀井 尚, 中野 徹, 里見 進

    日本内視鏡外科学会雑誌　19　(4)　465-470　2014年7月

    出版者・発行元： (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  4. Stage II-III食道癌に対する術前化学療法の成績

    小野寺 浩, 宮田 剛, 市川 宏文, 亀井 尚, 中野 徹, 里見 進

    日本消化器外科学会雑誌　46　(12)　877-884　2013年12月

    出版者・発行元： (一社)日本消化器外科学会

    ISSN： 0386-9768

    eISSN： 1348-9372

  5. 特発性食道破裂に対する胸腔鏡下手術

    小野寺 浩, 宮田 剛, 市川 宏文, 亀井 尚, 中野 徹, 高山 哲郎, 里見 進

    日本内視鏡外科学会雑誌　18　(3)　305-310　2013年5月

    出版者・発行元： (一社)日本内視鏡外科学会

    ISSN： 1344-6703

    eISSN： 2186-6643

  6. リンパ節転移を認めた食道腺扁平上皮癌の1例と食道腺扁平上皮癌の臨床病理学的特徴について

    洞口 正志, 宮田 剛, 小野寺 浩, 市川 宏文, 亀井 尚, 中野 徹, 谷山 裕亮, 岡本 宏史, 藤島 史喜, 里見 進

    日本消化器外科学会総会　67回　2-2　2012年7月

    出版者・発行元： (一社)日本消化器外科学会

  7. cStage II-III食道癌に対する術前化学療法の成績

    小野寺 浩, 宮田 剛, 市川 宏文, 亀井 尚, 中野 徹, 谷山 裕亮, 手島 仁, 三田村 篤, 中村 崇宣, 里美 進

    日本消化器外科学会総会　67回　2-2　2012年7月

    出版者・発行元： (一社)日本消化器外科学会

  8. 食道大細胞型神経内分泌癌の1切除例

    岡本 宏史, 藤島 史喜, 笠島 敦子, 宮田 剛, 小野寺 浩, 亀井 尚, 武山 大輔, 洞口 正志, 里見 進, 笹野 公伸

    日本消化器外科学会雑誌　45　(9)　914-922　2012年

    DOI： 10.5833/jjgs.45.914 　

  9. 食道癌に対する陽子線治療後のSalvage手術症例の検討

    日景 允, 宮田 剛, 小野寺 浩, 市川 宏文, 亀井 尚, 星田 徹, 菊池 寛, 中野 徹, 武山 大輔, 里見 進

    日本食道学会学術集会プログラム・抄録集　65回　335-335　2011年9月

    出版者・発行元： (NPO)日本食道学会

  10. 切除可能cStage II、III食道癌における術前化学療法(NAC)、手術単独、化学放射線療法(CRT)の比較

    亀井 尚, 宮田 剛, 小野寺 浩, 市川 宏文, 星田 徹, 菊池 寛, 中野 徹, 日景 允, 武山 大輔, 里見 進

    日本消化器外科学会総会　66回　553-553　2011年7月

    出版者・発行元： (一社)日本消化器外科学会

  11. cStageI食道癌の治療-手術vs根治的化学放射線療法

    亀井尚, 宮田剛, 小野寺浩, 市川宏文, 星田徹, 菊池寛, 中野徹, 日景允, 武山大輔, 里見進

    日本食道学会学術集会プログラム・抄録集　65th　2011年

  12. 食道胃接合部腺癌の占居部位,リンパ節転移,再発形式からのアプローチ法,切除範囲と郭清範囲の検討

    中野徹, 宮田剛, 小野寺浩, 市川宏文, 亀井尚, 星田徹, 菊池寛, 武山大輔, 日景允, 里見進

    日本消化器外科学会雑誌(Web)　44　(Supplement1)　2011年

    ISSN： 1348-9372

  13. 早期食道癌と重複した早期食道原発悪性黒色腫の1切除例および当院における食道原発悪性黒色腫の検討

    日景允, 神波力也, 宮田剛, 小野寺浩, 市川宏文, 亀井尚, 星田徹, 菊池寛, 中野徹, 里見進

    日本消化器外科学会雑誌(Web)　44　(Supplement1)　2011年

    ISSN： 1348-9372

  14. 食道癌salvage手術の根治性と安全性のバランス

    亀井尚, 宮田剛, 小野寺浩, 市川宏文, 星田徹, 菊池寛, 中野徹, 日景允, 武山大輔, 里見進

    日本食道学会学術集会プログラム・抄録集　65th　2011年

  15. 徹底ガイド 胃ろう(PEG)管理Q&A 3.PEG造設法 Q16 PEGの作り方には,どんな方法がありますか?

    小野寺浩

    ナーシングケアQ&A　(37)　2011年

    ISSN： 1349-0869

  16. 外科卒後研修 代謝栄養学をいかに学ぶか 医学部学生臨床実習における術後回復チェックリストの効用

    宮田 剛, 小野寺 浩, 市川 宏文, 亀井 尚, 星田 徹, 菊池 寛, 中野 徹, 殿塚 規雄, 手島 仁, 藤田 基生, 日景 允, 加藤 貴志, 後藤 均, 関口 悟, 川岸 直樹, 渡辺 道雄, 石田 孝宣, 佐藤 成, 大内 憲明, 里見 進

    外科と代謝・栄養　44　(3)　48-48　2010年6月

    出版者・発行元： 日本外科代謝栄養学会

    ISSN： 0389-5564

  17. 特発性食道破裂6例の検討

    神波 力也, 宮田 剛, 小野寺 浩, 市川 宏文, 亀井 尚, 星田 徹, 菊池 寛, 中野 徹, 瓶子 隆弘, 高橋 英幸, 里見 進

    日本外科学会雑誌　111　(臨増2)　543-543　2010年3月

    出版者・発行元： (一社)日本外科学会

    ISSN： 0301-4894

  18. 食道温存を目指したcStage I(T1bN0M0)食道癌に対する治療戦略

    亀井尚, 宮田剛, 小野寺浩, 市川宏文, 星田徹, 菊池寛, 中野徹, 手島仁, 日景允, 里見進

    日本食道学会学術集会プログラム・抄録集　64th　2010年

  19. Barrett食道癌の占居部位,リンパ節転移,再発形式からの術式の検討と接合部腺癌との比較

    中野徹, 宮田剛, 小野寺浩, 市川宏文, 亀井尚, 星田徹, 菊池寛, 日景允, 手島仁, 藤田基生, 里見進

    日本臨床外科学会雑誌　71　2010年

    ISSN： 1345-2843

  20. 当科における食道胃接合部腺癌の手術症例の検討

    中野徹, 宮田剛, 小野寺浩, 市川宏文, 亀井尚, 星田徹, 菊池寛, 手島仁, 日景允, 里見進

    日本食道学会学術集会プログラム・抄録集　64th　2010年

  21. 食道癌周術期の早期離床リハビリテーションが水分代謝,蛋白代謝に及ぼす影響

    加藤貴志, 武山大輔, 手島仁, 藤田基生, 日景允, 高橋英幸, 瓶子隆弘, 中野徹, 神波力也, 菊池寛, 星田徹, 亀井尚, 市川宏文, 小野寺浩, 宮崎修吉, 宮田剛, 佐藤成, 里見進

    外科と代謝・栄養　44　(3)　2010年

    ISSN： 0389-5564

  22. 食道癌症例における癌腫による基礎代謝の亢進の程度と術前FDG-PET画像による集積の関連性の検討

    三田村 篤, 加藤 貴志, 瓶子 隆弘, 高橋 英幸, 中野 徹, 神波 力也, 菊池 寛, 星田 徹, 亀井 尚, 市川 宏文, 小野寺 浩, 宮田 剛, 里見 進, 平出 智道, 高浪 健太郎, 福田 寛

    外科と代謝・栄養　43　(3)　115-115　2009年

    出版者・発行元： 日本外科代謝栄養学会

    ISSN： 0389-5564

    eISSN： 2187-5154

  23. 胸部食道癌に対する放射線化学療法後の再発様式の検討

    小野寺浩, 大内憲明, 宮崎修吉, 宮田剛, 市川宏文, 亀井尚, 星田徹, 菊池寛, 神波力也, 中野徹, 櫻井直, 桂一憲, 萩原資久, 里見進

    日本外科学会雑誌　109　(臨増2)　230-230　2008年

  24. 切除可能食道癌に対する根治的化学放射線療法とsalvage手術

    小野寺浩, 宮崎修吉, 宮田剛, 市川宏文, 亀井尚, 菊池寛, 神波力也, 阿部薫夫, 大内憲明, 里見進, 小川芳弘, 山田章吾, 吉岡孝志

    日本外科学会雑誌　108　(臨増2)　194-194　2007年

  25. V-14-5 胸腔鏡下食道切除術における術前3D-CTの有用性 : 気管血流に配慮した手術(食道2,ビデオセッション14,第61回日本消化器外科学会定期学術総会)

    市川 宏文, 宮崎 修吉, 宮田 剛, 森 隆弘, 小野寺 浩, 亀井 尚, 菊池 寛, 神波 力也, 森田 佳明, 里見 進

    日本消化器外科学会雑誌　39　(7)　2006年7月1日

    出版者・発行元： 一般社団法人日本消化器外科学会

    ISSN： 0386-9768

  26. 食道癌に対する化学放射線療法を含む集学的治療の新しい展開 Stage II-III食道癌に対する化学放射線療法+salvage手術

    小野寺浩, 宮崎修吉, 大内憲明, 里見進, 根本建二, 吉岡孝志

    日本癌治療学会誌　40　(2)　284-284　2005年

  27. 胸腔鏡手術を施行した特発性食道破裂の3例

    神波 力也, 宮崎 修吉, 宮田 剛, 森 隆弘, 小野寺 浩, 市川 宏文, 亀井 尚, 里見 進

    日本消化器外科学会雑誌　37　(7)　1129-1129　2004年7月

    出版者・発行元： (一社)日本消化器外科学会

    ISSN： 0386-9768

    eISSN： 1348-9372

  28. 同時性重複癌を有する食道癌の治療

    小野寺浩, 大内憲明, 宮崎修吉, 宮田剛, 森隆弘, 市川宏文, 亀井尚, 神波力也, 里見進

    日本消化器外科学会雑誌　37　(7)　1226-1226　2004年

  29. Upstream and downstream of erythroid transcription factor GATA-1

    M Yamamoto, S Takahashi, K Onodera, Y Muraosa, JD Engel

    GENES TO CELLS　2　(2)　107-115　1997年2月

    DOI： 10.1046/j.1365-2443.1997.1080305.x 　

    ISSN： 1356-9597

  30. GATA因子群およびNF‐E2をコードする遺伝子の構造と発現制御

    山本雅之, 本橋ほづみ, 小野寺浩, 高橋智, 峯岸直子, 伊東健, 蓬田健太郎, 五十嵐和彦

    日本分子生物学会年会プログラム・講演要旨集　18th　169　1995年11月

︎全件表示 ︎最初の5件までを表示

書籍等出版物 1

  1. 早期のがん治療法の選択 放射線治療

    山田章吾, d, 根本建二, 仲田栄子, 里見進, 小野寺浩, 山田章吾

    金原出版　2006年10月

講演・口頭発表等 24

  1. 脱毛治療でグリチルリチン酸内服後、偽性アルドステロン症から横紋筋融解をきたした 1 例

    小野寺 浩

    第23回 日本病院総合診療医学会学術総会　2021年9月19日

  2. 医学生の地域医療に関する意識調査

    小野寺 浩

    第17回日本病院総合診療医学会学術総会　2018年9月16日

  3. 原発巣CRで胸腔鏡下106recR郭清を行った３例

    小野寺浩, 宮田剛, 市川宏文, 亀井尚, 星田徹, 菊池寛, 中野徹, 里見進

    第64回日本食道学会学術集会　2010年8月31日

  4. 食道癌salvage手術における気管血流を考慮したリンパ節郭清

    小野寺浩, 宮田剛, 市川宏文, 亀井尚, 星田徹, 菊池寛, 中野徹, 里見進

    第65回日本消化器外科学会総会　2010年7月14日

  5. 特発性食道破裂6例の検討

    小野寺浩, 宮崎修吉, 宮田剛, 市川宏文, 亀井尚, 星田徹, 菊池寛, 中野徹, 高橋英幸, 里見進

    第46回日本腹部救急医学会総会　2010年3月18日

  6. 当科におけるStageII, III食道癌に対する治療戦略

    小野寺浩, 宮崎修吉, 宮田剛, 市川宏文, 亀井尚, 星田徹, 菊池寛, 中野徹, 里見進

    第64回日本消化器外科学会総会　2009年7月16日

  7. Chemoradiatin and salvage esophagectomy for treatment of resectable esophageal cancer 国際会議

    Onodera K, Miyazaki S, Satomi S

    4th Annual Academic Surgical Congress　2009年2月3日

  8. Stage I食道癌に対する手術とCRTの治療成績の比較

    小野寺浩, 宮崎修吉, 宮田剛, 市川宏文, 亀井尚, 星田徹, 菊池寛, 神波力也, 中野徹, 里見進

    日本消化器外科学会総会　2008年7月16日

  9. 胸部食道癌に対する放射線化学療法後の再発様式の検討

    小野寺浩, 大内憲明, 宮崎修吉, 宮田剛, 市川宏文, 亀井尚, 星田徹, 菊池寛, 神波力也, 中野徹, 里見進

    日本外科学会定期学術集会　2008年5月14日

  10. 切除可能胸部食道癌に対する根治的CRTとsalvage手術

    小野寺 浩, 大内 憲明, 宮崎 修吉, 宮田 剛, 里見 進

    弟６０回日本胸部外科学会　2007年10月17日

  11. 頚部食道癌に対する化学放射線療法？手術との治療成績の比較？

    小野寺 浩, 大内 憲明, 宮崎 修吉, 宮田 剛, 里見 進

    弟６２回日本消化器外科学会総会　2007年7月18日

  12. 切除可能Stage II, III胸部食道癌に対するCRT―手術との治療成績の比較―

    小野寺 浩, 大内 憲明, 宮崎 修吉, 宮田 剛, 里見 進

    弟６１回日本食道学会学術集会　2007年6月21日

  13. 胸部食道癌に対する根治的化学放射線療法後のsalvage手術

    小野寺 浩, 大内 憲明, 宮崎 修吉, 宮田 剛, 里見 進

    弟１０７回日本外科学会総会　2007年4月11日

  14. 切除可能胸部食道癌に対する化学放射線療法

    小野寺 浩

    北日本放射線腫瘍学研究会　2006年11月2日

  15. 切除可能食道癌 (Stage I-III)に対する化学放射線療法+salvage手術

    小野寺 浩

    東北外科集談会　2006年9月16日

  16. Chemoradiation therapy and salvage esophagectomy as curative treatments of esophageal carcinoma 国際会議

    小野寺 浩

    16th World Congress of the International Association of Surgeons & Gastroenterologists　2006年5月25日

  17. 手術可能食道癌(T1b-T3)に対する化学放射線療法+salvage手術

    小野寺 浩

    弟９２回日本消化器病学会総会　2006年4月20日

  18. StageII-III食道癌に対する化学放射線療法+salvage手術

    小野寺 浩

    弟４３回日本癌治療学会総会　2005年10月25日

  19. StageII,III胸部食道癌に対する手術とCRTの比較検討

    小野寺 浩

    第59回日本食道学会総会　2005年6月29日

  20. 切除可能な胸部食道癌に対する化学放射線療法とsalvage手術

    小野寺 浩

    多地点メディカルカンファランス（国立癌センター主催）　2005年1月27日

  21. 同時性重複癌を有する食道癌の治療

    小野寺 浩

    第59回日本消化器外科学会総会　2004年7月21日

  22. 切除可能な胸部食道癌に対する化学放射線療法

    小野寺 浩

    第58回日本食道学会学術集会　2004年6月24日

  23. Identification of possible marker genes for radiation sensitivity using cDNA microarray 国際会議

    小野寺 浩

    the IX World Congress of the International Society for Diseases of the Esophagus　2004年5月27日

  24. 食道癌細胞株を用いた放射線化学療法予後規定因子同定の試み

    小野寺 浩

    弟５７回日本食道学会学術集会　2003年6月27日

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 2

  1. Muse細胞を利用した食道再生の試み

    小野寺 浩

    2012年4月1日 ～ 2013年3月31日

  2. プロテオーム解析による放射線感受性規定因子の探求-感受性に基づいた食道癌の治療-

    小野寺 浩, 大内 憲明, 宮崎 修吉, 山田 章吾, 森 隆弘, 根本 建二

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    研究種目：Grant-in-Aid for Scientific Research (C)

    研究機関：Tohoku University

    2005年 ～ 2006年

    詳細を見る 詳細を閉じる

    RT-PCRによる放射線感受性マーカー発現の検討 放射線高感受性食道癌細胞と低感受性食道癌細胞に4Gyの照射を行い、抽出したRNAを定量的RT-PCR法により解析した。その結果、放射線低感受性細胞では放射線照射後にケモカイン受容体類似遺蛋白質であるSTRL33、ストレス反応蛋白質であるHSF-1の発現が約2倍に増加していることが明らかとなった。これらの変化は放射線高感受性細胞では観察されなかった。また、放射線高感受性細胞では放射線照射後に細胞周期調節蛋白質であるXRCC3の発現が増加してくることが明らかとなった。これらの遺伝子の放射線照射後の発現変化を調べることにより、食道癌の放射線感受性を治療前に予測することができる可能性が示された。 食道癌細胞に対する放射線照射後の蛋白質発現の変化 放射線高感受性食道癌細胞及び低感受性食道癌細胞に4Gyの照射を行い、照射後48時間で細胞をトリプシン処理にて回収し蛋白質を抽出、のpH3-10 NLプレキャストゲルにて一次元目電気泳動を行った後、10-20%プレキャストグラジェントゲルにて二次元目電気泳動を行い、蛋白質を分離した。照射を行わないコントロールの泳動パターンと比較することにより、放射線低感受性細胞において照射後に30kDaから60kDaまでの6種類の蛋白質の発現が増加してくることが明らかとなった。これらの放射線低感受性細胞に特徴的な発現変化は放射線高感受性細胞から抽出した蛋自質の泳動では観察されず、放射線低感受性細胞に特徴的な蛋白質の発現変化と解釈され、これらの蛋白質を放射線感受性マーカー蛋白質として利用できる可能性が示された。